Flag of the European Union EU Clinical Trials Register Help

Clinical trials for Cardiovascular Diseases AND Dyslipidemia AND Cholesterol, LDL

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   44336   clinical trials with a EudraCT protocol, of which   7366   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    35 result(s) found for: Cardiovascular Diseases AND Dyslipidemia AND Cholesterol, LDL. Displaying page 1 of 2.
    1  2  Next»
    EudraCT Number: 2015-001934-19 Sponsor Protocol Number: LPS14354 Start Date*: 2016-02-15
    Sponsor Name:Sanofi-Aventis Groupe
    Full Title: A Randomized, Open-Label, Parallel Group Study to Evaluate the Efficacy and Safety of Alirocumab Versus Usual Care in Patients with Type 2 Diabetes and Mixed Dyslipidemia at High Cardiovascular Ris...
    Medical condition: Dyslipidemia
    Disease: Version SOC Term Classification Code Term Level
    18.1 10027433 - Metabolism and nutrition disorders 10058108 Dyslipidaemia PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FI (Completed) DE (Completed) GB (Completed) SE (Completed) IT (Completed)
    Trial results: View results
    EudraCT Number: 2015-004735-12 Sponsor Protocol Number: 20130286 Start Date*: 2017-04-06
    Sponsor Name:Amgen Inc
    Full Title: A Double Blind, Randomized, Placebo Controlled, Multicenter Study toEvaluate Safety, Tolerability, and Efficacy on LDL-C of Evolocumab (AMG 145) in Subjects with HIV and with Hyperlipidemia and/or ...
    Medical condition: HIV and hyperlipidemia or mixed dyslipidemia.
    Disease: Version SOC Term Classification Code Term Level
    20.1 100000004861 10020604 Hypercholesterolemia LLT
    20.1 100000004861 10020667 Hyperlipidemia LLT
    20.0 100000004848 10020180 HIV positive LLT
    20.0 100000004861 10058110 Dyslipidemia LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Completed) PT (Completed) GB (Completed) BE (Completed) ES (Completed) GR (Completed) PL (Completed) IT (Completed)
    Trial results: View results
    EudraCT Number: 2016-004066-26 Sponsor Protocol Number: 20160250 Start Date*: 2017-08-16
    Sponsor Name:Amgen Inc
    Full Title: A Multicenter, Open-label, Single-arm, Extension Study to Assess Long-term Safety of Evolocumab Therapy in Subjects With Clinically Evident Cardiovascular Disease in Selected European Countries
    Medical condition: Dyslipidemia
    Disease: Version SOC Term Classification Code Term Level
    21.0 100000004861 10020604 Hypercholesterolemia LLT
    21.0 100000004861 10058110 Dyslipidemia LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Ongoing) SE (Completed) DK (Prematurely Ended) PT (Completed) BE (Prematurely Ended) IT (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2013-000723-14 Sponsor Protocol Number: 20120119 Start Date*: 2014-07-11
    Sponsor Name:Amgen Inc.
    Full Title: A Double-blind, Randomized, Placebo-Controlled, Multicenter Study to Evaluate Safety and Efficacy of Evolocumab (AMG 145) in Combination With Statin Therapy in Diabetic Subjects With Hyperlipidemia...
    Medical condition: Hyperlipidemia or mixed dyslipidemia in Diabetic Subjects
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Completed)
    Trial results: View results
    EudraCT Number: 2014-003213-29 Sponsor Protocol Number: SPh/02/2014 Start Date*: 2015-03-02
    Sponsor Name:SciencePharma spółka z ograniczoną odpowiedzialnością sp. j.
    Full Title: A randomized, multicenter, open-label, two-arm, parallel, phase III study to evaluate the efficacy and safety of nicotinic acid administered in combination with simvastatin for 6 months in comparis...
    Medical condition: Inhibiting the progression of atherosclerosis in patients with carotid arteries stenosis and dyslipidemia.
    Disease: Version SOC Term Classification Code Term Level
    17.1 10029205 - Nervous system disorders 10007687 Carotid artery stenosis PT
    17.1 100000004861 10058110 Dyslipidemia LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: PL (Completed)
    Trial results: (No results available)
    EudraCT Number: 2011-005924-16 Sponsor Protocol Number: M13-377 Start Date*: 2012-06-13
    Sponsor Name:Abbott Laboratories Ireland Limited
    Full Title: A 12-week, Double-blind, Randomized Study to Compare the Efficacy and Safety of Fixed Combinations of Fenofibrate /Simvastatin 145/20mg and Fenofibrate / Simvastatin 145/40mg Tablets vs. Matching M...
    Medical condition: Dyslipidemia
    Disease: Version SOC Term Classification Code Term Level
    14.1 100000004861 10058110 Dyslipidemia LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: CZ (Completed) PL (Completed)
    Trial results: View results
    EudraCT Number: 2020-002796-35 Sponsor Protocol Number: C4491011 Start Date*: 2021-01-07
    Sponsor Name:Pfizer Inc.
    Full Title: A Phase 2b Randomized, Double-Blind, Placebo-Controlled, Parallel Group, Dose Ranging Study to Assess the Efficacy, Safety, and Tolerability of Vupanorsen (PF 07285557) in Statin-Treated Participan...
    Medical condition: dyslipidemia
    Disease: Version SOC Term Classification Code Term Level
    21.0 100000004861 10058110 Dyslipidemia LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: PL (Completed)
    Trial results: View results
    EudraCT Number: 2020-000767-23 Sponsor Protocol Number: D7990C00003 Start Date*: 2020-11-12
    Sponsor Name:AstraZeneca AB
    Full Title: A Randomized, Parallel, Double-blind, Placebo-controlled, Dose-ranging, Phase 2b Study to Evaluate the Efficacy, Safety and Tolerability of AZD8233 Treatment in Participants With Dyslipidemia
    Medical condition: Dyslipidemia, especially: evaluation of low-density lipoprotein cholesterol reduction at steady state at different doses of AZD8233 in order to select a therapeutic dose.
    Disease: Version SOC Term Classification Code Term Level
    20.0 10027433 - Metabolism and nutrition disorders 10058108 Dyslipidaemia PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: SK (Completed) DK (Completed)
    Trial results: View results
    EudraCT Number: 2012-001398-97 Sponsor Protocol Number: 20110118 Start Date*: 2012-10-17
    Sponsor Name:Amgen Inc
    Full Title: A Double-blind, Randomized, Placebo-controlled, Multicenter Study Assessing the Impact of Additional LDL-Cholesterol Reduction on Major Cardiovascular Events When Evolocumab (AMG 145) is Used in Co...
    Medical condition: Dyslipidemia
    Disease: Version SOC Term Classification Code Term Level
    18.1 100000004861 10020604 Hypercholesterolemia LLT
    18.1 100000004861 10058110 Dyslipidemia LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FI (Completed) SK (Completed) PL (Completed) GR (Completed) LT (Completed) BE (Completed) IT (Completed) NL (Completed) DK (Completed) AT (Completed) HU (Completed) PT (Completed) ES (Completed) CZ (Completed) EE (Completed) IS (Completed) GB (Completed) DE (Completed) BG (Completed) SE (Completed) LV (Completed) IE (Completed) NO (Completed)
    Trial results: View results
    EudraCT Number: 2015-004780-36 Sponsor Protocol Number: 20130295 Start Date*: 2016-04-22
    Sponsor Name:Amgen Inc.
    Full Title: A Multicenter, Open-label, Single-arm, Extension Study to Assess Long-term Safety of Evolocumab Therapy in Patients With Clinically Evident Cardiovascular Disease
    Medical condition: Dyslipidemia
    Disease: Version SOC Term Classification Code Term Level
    21.0 100000004861 10020604 Hypercholesterolemia LLT
    21.0 100000004861 10058110 Dyslipidemia LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: SK (Completed) PL (Completed) HU (Completed) CZ (Completed)
    Trial results: View results
    EudraCT Number: 2014-000478-20 Sponsor Protocol Number: B1481045 Start Date*: 2014-10-21
    Sponsor Name:Pfizer Inc., 235 East 42nd Street, New York, ny 10017
    Full Title: A 52 WEEK, PHASE 3 DOUBLE-BLIND, RANDOMIZED, PLACEBOCONTROLLED, PARALLEL-GROUP STUDY TO ASSESS THE EFFICACY, SAFETY AND TOLERABILITY OF PF-04950615 IN SUBJECTS WITH PRIMARY HYPERLIPIDEMIA OR MIXED ...
    Medical condition: Primary Hyperlipidemia or mixed Dyslipidemia
    Disease: Version SOC Term Classification Code Term Level
    17.1 100000004861 10020667 Hyperlipidemia LLT
    17.1 100000004861 10058110 Dyslipidemia LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FI (Completed) GB (Completed) SE (Completed) CZ (Completed) NL (Completed) PL (Completed)
    Trial results: View results
    EudraCT Number: 2021-005065-40 Sponsor Protocol Number: TA-8995-302 Start Date*: 2022-05-13
    Sponsor Name:NewAmsterdam Pharma B.V.
    Full Title: Obicetrapib on Top of Maximum Tolerated Lipid-Modifying Therapies (BROADWAY): A Placebo-Controlled, Double-Blind, Randomized Phase 3 Study to Evaluate the Effect of 10 mg Obicetrapib in Participant...
    Medical condition: dyslipidemia heterozygous familial hypercholesterolemia (HeFH) atherosclerotic cardiovascular disease (ASCVD)
    Disease: Version SOC Term Classification Code Term Level
    20.1 100000004848 10020049 High cholesterol LLT
    20.0 100000004850 10057079 Heterozygous familial hypercholesterolemia LLT
    26.0 100000004866 10051615 Atherosclerotic cardiovascular disease LLT
    20.0 100000004866 10076622 Atherosclerotic plaque LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: NL (Completed) DK (Completed) CZ (Completed)
    Trial results: (No results available)
    EudraCT Number: 2013-002642-37 Sponsor Protocol Number: B1481019 Start Date*: 2014-01-24
    Sponsor Name:Pfizer Inc., 235 East 42nd Street, New York, NY 10017
    Full Title: A PHASE 3 DOUBLE-BLIND, RANDOMIZED, PLACEBO-CONTROLLED, PARALLEL-GROUP STUDY TO ASSESS THE EFFICACY, SAFETY AND TOLERABILITY OF PF-04950615 IN SUBJECTS WITH PRIMARY HYPERLIPIDEMIA OR MIXED DYSLIPID...
    Medical condition: primary hyperlipidemia or mixed dyslipidemia
    Disease: Version SOC Term Classification Code Term Level
    18.1 100000004861 10020667 Hyperlipidemia LLT
    18.1 100000004861 10058110 Dyslipidemia LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: CZ (Completed) DE (Completed) IT (Completed) PL (Completed)
    Trial results: View results
    EudraCT Number: 2013-002643-28 Sponsor Protocol Number: B1481020 Start Date*: 2013-12-10
    Sponsor Name:Pfizer Inc., 235 East 42nd Street, New York, NY 10017
    Full Title: A PHASE 3 DOUBLE-BLIND, RANDOMIZED, PLACEBO-CONTROLLED, PARALLEL-GROUP STUDY TO ASSESS THE EFFICACY, LONG-TERM SAFETY AND TOLERABILITY OF PF-04950615 IN SUBJECTS WITH PRIMARY HYPERLIPIDEMIA OR MIXE...
    Medical condition: primary hyperlipidemia or mixed dyslipidemia
    Disease: Version SOC Term Classification Code Term Level
    18.0 100000004861 10020667 Hyperlipidemia LLT
    18.0 100000004861 10058110 Dyslipidemia LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: LT (Completed) GB (Completed) ES (Completed) HU (Completed)
    Trial results: View results
    EudraCT Number: 2023-000166-33 Sponsor Protocol Number: SLICK-001 Start Date*: 2023-04-12
    Sponsor Name:Semmelweis University
    Full Title: Implementation study of lipid management of high-risk cardiovascular patients- Semmelweis Lipid Center for high-risk patients
    Medical condition: primary hypercholesterolaemia (heterozygous familial and non-familial) or mixed dyslipidaemia in atherosclerotic cardiovascular disease
    Disease: Version SOC Term Classification Code Term Level
    21.0 100000004861 10020604 Hypercholesterolemia LLT
    20.0 100000004850 10054380 Familial hypercholesterolemia LLT
    20.0 100000004850 10077966 Primary hypercholesterolemia LLT
    21.0 100000004861 10058110 Dyslipidemia LLT
    20.1 100000004861 10079969 Atherogenic dyslipidemia LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: HU (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2012-000575-17 Sponsor Protocol Number: FENOPRA-III-12-1 Start Date*: 2012-10-22
    Sponsor Name:Laboratoires SMB S.A.
    Full Title: A phase III, two-armed, randomised, double blind, parallel study to compare the efficacy and safety in high CHD-risk patients with mixed dyslipidaemia of a 12-week administration of a fixed dose co...
    Medical condition: mixed dyslipidaemia
    Disease: Version SOC Term Classification Code Term Level
    16.0 10027433 - Metabolism and nutrition disorders 10058108 Dyslipidaemia PT
    16.0 10027433 - Metabolism and nutrition disorders 10070901 Diabetic dyslipidaemia PT
    16.0 10007541 - Cardiac disorders 10007649 Cardiovascular disorder PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: BG (Completed) LV (Completed) HR (Completed)
    Trial results: View results
    EudraCT Number: 2011-001007-12 Sponsor Protocol Number: MK-0524B-143 Start Date*: 2011-07-29
    Sponsor Name:Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc.
    Full Title: A Phase III Multicenter, Double-Blind, Crossover Design Study to Evaluate Lipid-Altering Efficacy and Safety of 1 g/10 mg Extended-Release Niacin/Laropiprant/Simvastatin Combination Tablets in Pati...
    Medical condition: Primary Hypercholesterolemia & Mixed Dyslipdemia
    Disease: Version SOC Term Classification Code Term Level
    13.1 10027433 - Metabolism and nutrition disorders 10058110 Dyslipidemia LLT
    13.1 10027433 - Metabolism and nutrition disorders 10020604 Hypercholesterolemia LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Prematurely Ended) DE (Prematurely Ended) LT (Prematurely Ended) NL (Prematurely Ended) LV (Prematurely Ended) CZ (Prematurely Ended) NO (Prematurely Ended) SK (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2010-023939-42 Sponsor Protocol Number: MK-0524B-118 Start Date*: 2011-05-18
    Sponsor Name:Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc.
    Full Title: A Phase III Multicenter, Double-Blind, Crossover Design Study to Evaluate Lipid-Altering Efficacy and Safety of Extended-Release Niacin/Laropiprant/Simvastatin Combination Tablet in Patients with P...
    Medical condition: Primary Hypercholesterolemia & Mixed Dyslipdemia
    Disease: Version SOC Term Classification Code Term Level
    13.1 10027433 - Metabolism and nutrition disorders 10058110 Dyslipidemia LLT
    13.1 10027433 - Metabolism and nutrition disorders 10020604 Hypercholesterolemia LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: HU (Completed) DE (Prematurely Ended) BG (Prematurely Ended) ES (Completed) IT (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2014-005378-12 Sponsor Protocol Number: CL3-05153-006 Start Date*: 2016-01-05
    Sponsor Name:Institut de Recherche Internationales Servier
    Full Title: Efficacy and Safety of Fixed-Dose Combination atorvastatin/amlodipine/perindopril versus Fixed-Dose Combination of atorvastatin/ amlodipine in Patients with Hypertension and Dyslipidemia.
    Medical condition: hypertension and dyslipidemia
    Disease: Version SOC Term Classification Code Term Level
    19.0 100000004866 10020774 Vascular hypertensive disorders NEC HLT
    19.0 100000004861 10058110 Dyslipidemia LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: BG (Completed) IT (Completed)
    Trial results: View results
    EudraCT Number: 2021-005064-22 Sponsor Protocol Number: TA-8995-301 Start Date*: 2022-09-22
    Sponsor Name:NewAmsterdam Pharma B.V.
    Full Title: Obicetrapib on Top of Maximum Tolerated Lipid-Modifying Therapies (BROOKLYN): A Placebo-Controlled, Double-Blind, Randomized, Phase 3 Study to Evaluate the Effect of 10 mg Obicetrapib in Partici...
    Medical condition: dyslipidemia heterozygous familial hypercholesterolemia (HeFH)
    Disease: Version SOC Term Classification Code Term Level
    20.1 100000004848 10020049 High cholesterol LLT
    20.0 100000004850 10057079 Heterozygous familial hypercholesterolemia LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Ongoing) NL (Completed) CZ (Completed) PL (Completed)
    Trial results: (No results available)
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    1  2  Next»
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Sat May 17 09:16:42 CEST 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA